QTTB — Q32 Bio Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2018-03-28.
Performance
Technicals
Others in Healthcare
Measured signals that fired on QTTB
| date | signal | measured base rate |
|---|---|---|
| 2026-07-16 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-07-13 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-01 | Cluster buy: three or more insiders insider | +0.63% over 21 days · t = 1.84 · n = 3,050 not distinguishable from its control group |
| 2026-05-27 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-02-27 | Cluster sale: three or more insiders insider | -0.37% over 21 days · t = -3.38 · n = 21,542 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-16 | Kalowski Lee CFO and President | Grant or award | 53.2K | 0.00 | 0 |
| 2026-07-16 | Violette Shelia M. Chief Scientific Officer | Grant or award | 37.5K | 0.00 | 0 |
| 2026-07-16 | Morrison Jodie Pope CEO | Grant or award | 132.0K | 0.00 | 0 |
| 2026-06-30 | Manke Isaac Director | Option exercise | 53.5K | 2.80 | 149.9K |
| 2026-05-28 | ORBIMED ADVISORS LLC Director | Open-market purchase | 1.2M | 8.00 | 10.0M |
| 2026-05-28 | OrbiMed Capital GP VII LLC Director | Open-market purchase | 1.2M | 8.00 | 10.0M |
| 2026-05-28 | Xu Diyong Director | Open-market purchase | 1.2M | 8.00 | 10.0M |
| 2026-05-28 | OrbiMed Genesis GP LLC Director | Open-market purchase | 1.2M | 8.00 | 10.0M |
| 2026-05-28 | OrbiMed Genesis GP LLC Director | Open-market purchase | 625.0K | 8.00 | 5.0M |
| 2026-05-28 | OrbiMed Capital GP VII LLC Director | Open-market purchase | 625.0K | 8.00 | 5.0M |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| ORBIMED ADVISORS LLC | 14.5M | 2.3M |
| Atlas Venture Life Science Advisors, LLC | 13.4M | 2.1M |
| Opaleye Management Inc. | 8.1M | 1.3M |
| Carlyle Group Inc. | 7.1M | 1.1M |
| ARCH Venture Management, LLC | 2.1M | 320.5K |
| ACORN CAPITAL ADVISORS, LLC | 2.0M | 315.1K |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.0M | 306.4K |
| MACKENZIE FINANCIAL CORP | 1.6M | 246.3K |
| Sanofi | 1.6M | 244.1K |
| RENAISSANCE TECHNOLOGIES LLC | 1.3M | 206.9K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| 10-Q | 2026-08-05 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-05 | 2026-08-05 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-07-31 | — | on EDGAR ↗ |
| EFFECT | 2026-07-28 | — | on EDGAR ↗ |
| 424B3 | 2026-07-28 | — | on EDGAR ↗ |
| 4/A | 2026-07-21 | 2026-06-12 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Ask the AI about QTTB
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →